Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss implications of the potentially large patient population during 26 September public meeting of the Midwest CEPAC.
The ICER today released an evidence report assessing the comparative clinical effectiveness and value of rivaroxaban (Xarelto, Janssen Pharmaceuticals) and icosapent ethyl (Vascepa, Amarin Pharma) as additive cardiovascular disease therapies.
This Evidence Report will be reviewed at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), in St. Louis, MO on 26 September 2019.
